
Phinomics is a pioneering company at the intersection of biology and AI, focusing on circular DNA to revolutionize precision oncology and drug discovery. Their flagship product, the Circulome Atlas, is a patented dataset that maps circular DNA across various tissues and conditions, enabling the identification of novel biomarkers and therapeutic targets. Founded by experts in DNA biophysics and data science, Phinomics aims to address urgent healthcare challenges through innovative genomic technologies, positioning itself as a leader in precision medicine.

Phinomics is a pioneering company at the intersection of biology and AI, focusing on circular DNA to revolutionize precision oncology and drug discovery. Their flagship product, the Circulome Atlas, is a patented dataset that maps circular DNA across various tissues and conditions, enabling the identification of novel biomarkers and therapeutic targets. Founded by experts in DNA biophysics and data science, Phinomics aims to address urgent healthcare challenges through innovative genomic technologies, positioning itself as a leader in precision medicine.
Founded: 2020
Headquarters: San Carlos, California
Focus: Isolating and decoding extrachromosomal circular DNA and cryptic microproteins (the circulome) for precision medicine
Flagship product: Circulome Atlas (patented dataset)
Known investors: Springboard Health Angels
Precision medicine, biomarker discovery, therapeutic target identification using novel genomic signals (extrachromosomal circular DNA and microproteins).
2020
Biotechnology
Public profiles list a seed entry in May 2022; amount not disclosed in provided evidence.
“Springboard Health Angels”